Drug Trial Radar · NCT05238701
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Feb 25, 2022
Primary completion
Nov 4, 2023
Study completion Nov 4, 2023
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.
Conditions
- Huntington Disease
- Tardive Dyskinesia
Interventions
LPM3770164 sustained release tabletDrug
LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
LPM3770164 sustained release tablet simulantDrug
LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse effectsTime frame: from baseline to day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.